Skip to content

    Leukemia & Lymphoma

    Font Size

    Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Noncontiguous Stage II / III / IV Adult NHL



    Obinutuzumab is an alternative CD20-binding monoclonal antibody with alternative epitope binding and is being studied in patients with recurrent follicular lymphoma. This agent has shown responses in 20% to 30% of patients when used alone and in 80% of patients when combined with CHOP or FC (fludarabine and cyclophosphamide) in relapsed follicular lymphoma patients.[45,46][Level of evidence: 3iiiDiv]

    Purine nucleoside analogs

    • Fludarabine.[1,47,48]
    • 2-chlorodeoxyadenosine.[49,50]

    Alkylating agents (with or without steroids)


    Evidence (bendamustine):

    1. In a prospective, randomized trial NCT00991211, 527 patients with indolent and mantle cell lymphoma were randomly assigned to a bendamustine-plus-rituximab arm versus an R-CHOP arm.[29][Level of evidence: 1iiDiii]
      • With a median follow-up of 45 months, the median PFS favored the bendamustine arm (69 months vs. 31 months [HR, 0.58; 95 % confidence intervaI (CI), 0.44-0.74; P < .0001]) but with no difference in OS.
      • The bendamustine arm was associated with significantly lower rates of alopecia, hematologic toxicity, stomatitis, peripheral neuropathy, and infections than was the R-CHOP arm.

    Combination chemotherapy

    • CVP: cyclophosphamide + vincristine + prednisone.[1,52]
    • CVP followed by rituximab maintenance.[53]
    • C-MOPP: cyclophosphamide + vincristine + procarbazine + prednisone.[54,55]
    • CHOP: cyclophosphamide + doxorubicin + vincristine + prednisone.[51,56] A Cochrane meta-analysis could not identify any OS benefit to adding doxorubicin to chemotherapy regimens with rituximab or to chemotherapy regimens without rituximab.[36][Level of evidence: 1iiA]
    • FND: fludarabine + mitoxantrone +/- dexamethasone, as evidenced in the SWOG-9501 trial, for example.[57,58]

    Yttrium-90-labeled ibritumomab tiuxetan and iodine-131-labeled tositumomab

    Yttrium-90-labeled ibritumomab tiuxetan and iodine-131-labeled tositumomab are available for previously untreated and relapsing patients with minimal (<25%) or no marrow involvement with lymphoma.[59,60,61] In a randomized, prospective trial, 554 patients with previously untreated advanced-stage follicular lymphoma received either R-CHOP times six cycles or CHOP times six cycles followed by I-131 tositumomab radioimmunotherapy (RIT); with a median follow-up of 4.9 years, there was no significant difference between the PFS and OS (2-year OS, R-CHOP, 97%; CHOP-RIT, 93%; P = .08).[62][Level of evidence: 1iiD] Because a significant prolongation of PFS was seen for R-CHOP followed by rituximab maintenance compared with R-CHOP alone,[63] this lack of benefit for CHOP-RIT was particularly disappointing. Iodine-131-labeled tositumomab became commercially unavailable in 2013.

    1 | 2 | 3 | 4 | 5
    Next Article:

    Today on WebMD

    stem cells
    What are they and why do we need them?
    Lung cancer xray
    See it in pictures, plus read the facts.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Do you know the symptoms?
    Vitamin D
    New Treatments For Non-Hodgkins Lymphoma
    Lifestyle Tips for Depression Slideshow
    Pets Improve Your Health